No differential effect of beverages sweetened with fructose, high-fructose corn syrup, or glucose on systemic or adipose tissue inflammation in normal-weight to obese adults: a randomized controlled trial

Am J Clin Nutr. 2016 Aug;104(2):306-14. doi: 10.3945/ajcn.115.129650. Epub 2016 Jun 29.

Abstract

Background: Sugar-sweetened beverage (SSB) consumption and low-grade chronic inflammation are both independently associated with type 2 diabetes and cardiovascular disease. Fructose, a major component of SSBs, may acutely trigger inflammation, which may be one link between SSB consumption and cardiometabolic disease.

Objective: We sought to determine whether beverages sweetened with fructose, high-fructose corn syrup (HFCS), and glucose differentially influence systemic inflammation [fasting plasma C-reactive protein and interleukin-6 (IL-6) as primary endpoints] acutely and before major changes in body weight. Secondary endpoints included adipose tissue inflammation, intestinal permeability, and plasma fetuin-A as potential mechanistic links between fructose intake and low-grade inflammation.

Design: We conducted a randomized, controlled, double-blind, crossover design dietary intervention (the Diet and Systemic Inflammation Study) in 24 normal-weight to obese adults without fructose malabsorption. Participants drank 4 servings/d of fructose-, glucose-, or HFCS-sweetened beverages accounting for 25% of estimated calorie requirements while consuming a standardized diet ad libitum for three 8-d periods.

Results: Subjects consumed 116% of their estimated calorie requirement while drinking the beverages with no difference in total energy intake or body weight between groups as reported previously. Fasting plasma concentrations of C-reactive protein and IL-6 did not differ significantly at the end of the 3 diet periods. We did not detect a consistent differential effect of the diets on measures of adipose tissue inflammation except for adiponectin gene expression in adipose tissue (P = 0.005), which was lowest after the glucose phase. We also did not detect consistent evidence of a differential impact of these sugars on measures of intestinal permeability (lactulose:mannitol test, plasma zonulin, and plasma lipopolysaccharide-binding protein).

Conclusion: Excessive amounts of fructose, HFCS, and glucose from SSBs consumed over 8 d did not differentially affect low-grade chronic systemic inflammation in normal-weight to obese adults. This trial was registered at clinicaltrials.gov as NCT01424306.

Keywords: adipose tissue inflammation; fructose; intestinal permeability; sugar-sweetened beverages; systemic inflammation.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adiponectin / metabolism
  • Adipose Tissue / metabolism*
  • Adipose Tissue / pathology
  • Adult
  • Beverages*
  • Body Mass Index
  • C-Reactive Protein / metabolism
  • Diet*
  • Double-Blind Method
  • Feeding Behavior
  • Female
  • Fructose / pharmacology
  • Glucose / pharmacology
  • Hexoses / pharmacology*
  • High Fructose Corn Syrup / pharmacology*
  • Humans
  • Inflammation* / blood
  • Interleukin-6 / blood
  • Male
  • Middle Aged
  • Obesity / metabolism
  • Obesity / pathology*
  • Reference Values
  • Sweetening Agents / pharmacology
  • Young Adult

Substances

  • Adiponectin
  • Hexoses
  • High Fructose Corn Syrup
  • IL6 protein, human
  • Interleukin-6
  • Sweetening Agents
  • Fructose
  • C-Reactive Protein
  • Glucose

Associated data

  • ClinicalTrials.gov/NCT01424306